Cancer Treatment Monitoring with EFIRM

MDPI cancers has recently published an exciting paper regarding liquid biopsy and its potential applications in therapeutic treatment monitoring. A cohort of 22 lung cancer subjects with samples taken periodically over a period of 61 to 272 days was evaluated with EFIRM, NGS, and ddPCR.

This publication was a project including authors from EZLife Bio, the National Cancer Institute, and UCLA. Read more about it below!

Link on the Cancers Website

Back to blog